Nilandron (sanofi-aventis U.S. LLC)
Welcome to the PulseAid listing for the Nilandron drug offered from sanofi-aventis U.S. LLC. This Androgen Receptor Antagonists [MoA],Androgen Receptor Inhibitor [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | sanofi-aventis U.S. LLC |
NON-PROPRIETARY NAME: | Nilutamide |
SUBSTANCE NAME: | NILUTAMIDE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Androgen Receptor Antagonists [MoA],Androgen Receptor Inhibitor [EPC] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 1996-09-19 |
END MARKETING DATE: | 0000-00-00 |
Nilandron HUMAN PRESCRIPTION DRUG Details:
Item Description | Nilandron from sanofi-aventis U.S. LLC |
LABELER NAME: | sanofi-aventis U.S. LLC |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 150(mg/1) |
START MARKETING DATE: | 1996-09-19 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 0088-1111_7fc5e6f1-25b1-45b6-9655-35d094c9cc89 |
PRODUCT NDC: | 0088-1111 |
APPLICATION NUMBER: | NDA020169 |
Other NILUTAMIDE Pharmaceutical Manufacturers / Labelers: